Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines

Clinical Cancer Research

Volumn 5, Issue 3, 1999, Pages 643-654

  Van Triest, Baukelien ^a   Pinedo, Herbert M ^a   Van Hensbergen, Yvette ^a   Smid, Kees ^a   Telleman, Frank ^a   Schoenmakers, Pascale S ^a   Van Der Wilt, Clasina L ^a   Van Laar, Jan A M ^a   Noordhuis, Paul ^a   Jansen, Gerrit ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; METHOTREXATE; NOLATREXED; PEMETREXED; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

ARTICLE; CELL DIFFERENTIATION; COLON CANCER; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME BLOOD LEVEL; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIMETABOLITES, ANTINEOPLASTIC; BINDING SITES; BIOLOGICAL TRANSPORT; BLOTTING, WESTERN; CATALYSIS; CELL DIVISION; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FLUORODEOXYURIDYLATE; FLUOROURACIL; FOLIC ACID ANTAGONISTS; HUMANS; PEPTIDE SYNTHASES; PTEROYLPOLYGLUTAMIC ACIDS; THYMIDYLATE SYNTHASE; TRITIUM; TUMOR CELLS, CULTURED;

EID: 0032994840     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Moertel, C. G. Chemotherapy for colorectal cancer. N. Engl. J. Med., 326: 1136-1142, 1994.
2. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rates. J. Clin. Oncol., 10: 869-903, 1992.
3. Haller, D. G., An overview of adjuvant therapy for colorectal cancer. Eur. J. Cancer, 31A: 1255-1263, 1995.
4. Pinedo, H. M., and Peters, G. J. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol., 6: 1653-1664, 1988.
5. Houghton, J. A., Williams, L. G., De Graaf, S. S. N., Cheshire, P. J., Rodman, J. H., Maneval, D. C., Wainer, I. W., Jadaud, P., and Houghton, P. J. Relationship between dose rate of [6RS]leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res., 50: 3493-3502, 1990.
6. Van der Wilt, C. L., and Peters, G. J. New targets for pyrimide antimetabolites for the treatment of solid tumors. I. Thymidylate synthase. Pharm. World Sci., 16: 84-103, 1994.
7. Arbuck, S. G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer (Phila.), 6: 1036-1047, 1989.
8. Labianca, R., Pessi, A., Facendola, G., Pirovano, M., and Luporini, G. Modulated 5-fluorouracil (5-FU) regimens in advanced colorectal cancer: a critical review of comparative studies. Eur. J. Cancer, 32A (Suppl. 5): S7-S12, 1996.
9. Peters, G. J., and Jansen, G. Resistance to antimetabolites. In: R. L. Schilsky, G. A. Milano, and M. J. Ratain (eds.), Principles of Antineoplastic Drug Development and Pharmacology, pp. 543-585. New York: Marcel Dekker, Inc., 1996.
10. Rustum, Y. M., Harstrick, A., Cao, S., Vanhoefer, U., Yin, M-B., Wilke, H., and Seeber, S. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J. Clin. Oncol., 15: 389-400, 1997.
11. Cunningham, D., Zalcberg, J. R., Rath, U., Olver, I., Van Cutsem, E., Svensson, C., Seitz, J. F., Harper, P., Kerr, D., Perez-Manga, G. Azub, M., Seymour, L., Lowerg, K., and the "Tomudex" Colorectal Cancer Study Group. (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The "Tomudex" Colorectal Cancer Study Group. Eur. J. Cancer, 31A: 1945-1954, 1995.
12. Duch, D. S., Banks, S., Dev, I. K., Dickerson, S. H., Ferone, R., Heath, L. S., Humphreys, J., Knick, V., Pendergast W., Singer, S., Smith, G. K., Waters, K., and Wilson, H. R. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res., 53: 810-818, 1993.
13. Rinaldi, D. A., Burris, H. A., Dorr, F. A., Woodworth, J. R., Kuhn, J. G., Eckardt, J. R., Rodriguez, G., Corso, S. W., Fields, S. M., and Langley, C. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J. Clin. Oncol., 13: 2842-2850, 1995.
14. Rafi, I., Taylor, G. A., Calvete, J. A., Boddy, A. V., Balmanno, K., Bailey, N., Lind, M., Calvert, A. H., Webber, S., Jackson, R. C., Johnston, A., Clendeninn, N., and Newell, D. R. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridolthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion. Clin. Cancer Res., 1: 1275-1284, 1995.
15. Westerhof, G. R., Schornagel, J. H., Kathmann, I., Jackman, A. L., Rosowsky, A., Forsch, R. A., Hynes, J. B., Boyle, F. T., Peters, G. J., Pinedo, H. M., and Jansen, G. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular structure and biological activity. Mol. Pharmacol., 48: 459-471, 1995.
16. Hanlon, M. H., and Ferone, R. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase. Cancer Res., 56: 3301-3306, 1996.
17. Shin, C., Chen, V. J., Gossett, L. S., Gates, S. B., MacKellar, W. C., Habeck, L. L., Shackelford, K. A., Mendelsohn, L. G., Soose, D. J., Patel, V. F., Andis, S. L., Bewley, J. R., Rayl, E. A., Moroson, B. A., Beardsley, G. P., Kohler, W., Ratnam, M., and Schultz, R. M. LY231514, a pyrrolo[2,3-D]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res., 57: 1116-1123, 1997.
18. Webber, S., Bartlett, C. A., Boritzki, T. J., Hillard, J. A., Howland, E. F., Johnston, A. L., Kosa, M., Margosiak, S. A., Morse, C. A., and Shetty, B. V. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother. Pharmacol., 37: 509-517, 1996.
19. Beck, A., Etienne, M. C., Chradame, S., Fischel, J. L., Formento, P., Rene, N., and Milano, G. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil. Eur. J. Cancer, 10: 1408-1411, 1994.
20. Johnston, P. G., Drake, J. C., Trepel, J., and Allegra, C. J. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res., 52: 4306-4312, 1992.
21. Peters, G. J., Van der Wilt, C. L., Van Groeningen, C. J., Smid, K., Meijer, S., and Pinedo, H. M. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J. Clin. Oncol., 12: 2035-2042, 1994.
22. Leichman, L., Lenz, H-J., Leichman, C. G., Groshen, S., Danenberg, K., Baranda, J., Spears, C. P., Boswell, W., Silberman, H., Ortega, A., Stain, S., Beart, R., and Danenberg, P. Quantitation of intratumoral thymidylate synthase expression predicts for resistance to protracted infusion of 5-fluorouracil and weekly leucovorin in disseminated colorectal cancers: preliminary report from an ongoing trial. Eur. J. Cancer, 31: 1306-1310, 1995.
23. Lenz, H-J., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Groshen, S., Cohen, H., Crookes, P., Silberman, H., Baranda, J., Garcia, Y., Li. J., and Leichman, L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol., 14: 176-182, 1996.
24. Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., and Allegra, C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
25. Fischel, J. L., Chazal, M.. Chéradame, S., Formento, P., Renee, N., Formento, J. L., Francoual, M., and Milano, G. Biochemical determinants for relative tumor sensitivity to Raltitrexed (Tomudex, TX) and 5-fluourouracil (FU). Proc. Am. Assoc. Cancer Res., 38: 3188, 1997.
26. Chazal, M., Chéradame, S., Formento, J. L., Francoual, M., Formento, P., Etienne, M. C., François, E., Richelme, H., Mousseau, M., Letoublon, C., Pezet, D., Cur, H., Seitz, J. F., and Milano, G. Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data. Clin. Cancer Res., 3: 553-557, 1997.
27. Etienne, M. C., Guillot, T., and Milano, G. Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy. Ann. Oncol., 7: 283-289, 1996.
28. Lu, K., Yin, M-B., McGuire, J. J., Bonmassar, E., and Rustum, Y. M., Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2- thenoyl]-1-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Biochem. Pharmacol., 50: 391-398, 1995.
29. Drake, J. C., Allegra, C. J., Moran, R. G., and Johnston, P. G. Resistance to Tomudex (ZD1694): multifactorial in human breast and colon carcinoma cell lines. Biochem. Pharmacol., 51: 1349-1355, 1996.
30. Jackman, A. L., Kelland, L. R., Kimbell, R., Brown, M., Gibson, W., Aherne, G. W., Hardcastle, A., and Boyle, F. T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br. J. Cancer, 71: 914-924, 1995.
31. Peters, G. J., Laurensse, E., Leyva, A., Lankelma, J., and Pinedo, H. M. Sensitivity of human, murine and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res., 46: 20-28, 1986.
32. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
33. Park, J-G, Kramer, B. S., Steinberg, S. M., Carmichael, J., Collins, J. M., Minna, J. D., and Gazdar, A. F. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res., 47: 5875-5879, 1987.
34. Rutzky, L. P. The biology of human colon tumor cells in culture. Adv. Cell Cult., 4: 47-83, 1985.
35. Skehan, P., Storeng, R, Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bohesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst., 82: 107-112, 1990.
36. Peters, G. J., Wets, M., Keeper, Y. P., Oskam, R., Van Ark-Otte, J., Noordhuis, P., Smid, K., and Pinedo, H. M. Transformation of mouse fibroblasts with the oncogenes H-Ras or TRK is associated with pronounced changes in drug sensitivity and metabolism. Int. J. Cancer, 3: 450-455, 1993.
37. Chou, T. C., and Talalay P. Quantitative analysis of dose-effect relationship: the combined effect of multiple drugs on enzyme inhibitors. In: G. Weber (ed.), Advances in Enzyme Regulation, pp. 27-55. New York: Pergamon Press, 1983.
38. Peters, G. J., Van Groeningen, C. J., Laurensse, E., and Pinedo, H. M. Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2′-deoxyuridine-5′-monophophate. Eur. J. Cancer, 27: 263-267, 1991.
39. Peters, G. J., Laurensse, E., Leyva, A., and Pinedo, H. M. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur. J. Cancer Clin. Oncol., 23: 1869-1881, 1987.
40. Van Triest, B., Pinedo, H. M., Telleman, F., Van der Wilt, C. L., Jansen, G., and Peters, G. J. Cross-resistance to antifolates in multidrug resistant cell lines with P-glycoprotein or multidrug resistance protein expression. Biochem. Pharmacol., 53: 1855-1866, 1997.
41. Van der Wilt, C. L., Smid, K., Aherne, G. W., Noordhuis, P., and Peters, G. J. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur. J. Cancer, 33: 471-478, 1997.
42. Freemantle, S. J., Aherne, G. W., Hardcastle, A., Lunec, J., and Calvert, A. H. Increases in thymidylate synthase protein levels measured using newly developed antibodies. Proc. Am. Assoc. Cancer Res., 32: 360, 1991.
43. Van der Wilt, C. L., Cloos, J., De Jong, M., Pinedo, H. M., and Peters, G. J. Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity. Oncol. Res., 7: 317-321, 1995.
44. Braakhuis, B. J. M., Jansen, G., Noordhuis, P., Kegel, A., and Peters, G. J. Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaminopterin against human head and neck squamous cell carcinoma. Biochem. Pharmacol., 46: 2155-2161, 1993.
45. Van der Laan, B. F. A. M., Jansen, G., Kathmann, G. A. M., Westerhof, G. R., Schornagel, J. H., and Hordijk, G. J. In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate. Int. J. Cancer. 51: 909-914, 1992.
46. Jackman, A. L., Taylor, G. A., Gibson, W., Kimbell, R., Brown, M., Calvert, A. H., Judson, I. R., and Hughes, L. R. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res., 51: 5579-5586, 1991.
47. Wang, F-S., Aschele, C., Sobrero, A., Chang, Y-M, and Bertino, J. R. Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. Cancer Res., 53: 3677-3680, 1993.
48. McGuire, J. J., Heitzman, K. J., Haile, W. H., Russell, C. A., McCloskey, D. E., and Piper, J. R. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines. Leuk. Res., 7: 1996-2003, 1993.
49. Jansen, G., Mauritz, R., Assaraf, Y. G., Sprecher, H., Drori, S., Kathmann, I., Westerhof, G. R., Priest, D. G., Bunni, M., Pinedo, H. M., Schornagel, J. H., and Peters, G. J. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and -resistant leukemia cells. Adv. Enzyme Regul., 37: 59-76, 1997.
50. Jansen, G., Mauritz, R., Drori, S., Sprecher, H., Kathmann, I., Bunni, M., Priest, D. G., Noordhuis, P., Schornagel, J. H., Pinedo, H. M., Peters, G. J., and Assaraf, Y. G. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem., 273: 30189-30198, 1998.
51. Tse, A., and Moran, R. G. Cellular folates prevent polyglutamylation of 5,10-dideazatetrahydrofolate. A novel mechanism of resistance to folate antimetabolites. J. Biol. Chem., 273: 25944-25952. 1998.
52. Rees, C., Kimbell, R., Valenti, M., Brunton, L., Farrugia, D., and Jackman, A. L. Effects of leucovorin (LV) and folic acid (FA) on the cytotoxicity of the thymidylate synthase (TS) inhibitors, Tomudex (ZD1694) and ZD9331. Proc. Am. Assoc. Cancer Res., 38: 3184, 1997.
53. Zervos, P. H., Allen, R. H., Thornton, D. E., and Thiem, P. A. Functional folate status as a prognostic indicator of toxicity in clinical trials of the multitargeted antifolate LY231514. Eur. J. Cancer, 33 (Suppl.): S18, 1997.
54. Smid, K., Van der Wilt, C. L., and Peters, G. J. Effects of novel antifolates on the binding of 5-flouro-2′-deoxyuridine-57prime;-monophosphate (FdUMP) to bacterial and human TS. Ann. Oncol., 7(suppl. 1): 310, 1996.
55. Stout, T. J., and Stroud, R. M. The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0A resolution: implications for a new mode of inhibition. Structure, 4: 67-77, 1996.
56. Johnston, P. G., Mick, R., Recant, W., Behan, K. A., Dolan, M. E., Ratain, M. J., Beckmann, E., Weichselbaum, R. R., Allegra, C. J., and Vokes, E. E. Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J. Natl. Cancer Inst., 89: 308-313, 1997.
57. Farrugia, D., Cunningham, D., Danenberg, P., Danenberg, K., Metzger, R., Mitchell, F., MacVicar, D., McCarthy, K., Aherne, G. W., Norman, A., and Jackman, A. L. A pharmacodynamic (PD) study of the thymidylate synthase (TS) inhibitor Tomudex in advanced colorectal cancer (CRC). Proc. Am. Assoc. Cancer Res., 38: 4132, 1997.